Cancer Risk Mouse Study Suppliers In Usa Massachusetts

Alkermes is focused on developing innovative medicines that aim to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated global biopharmaceutical company, we apply our scientific expertise and ...

INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...

Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, ...

Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...

Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...

AMSBIO is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, ...

Cambridge Isotope Laboratories, Inc. (CIL) is the world’s leading producer of stable isotopes and stable isotope-labeled compounds. With over 400 employees and laboratories in four countries, CIL specializes in the process of labeling biochemical ...

Founded in 2007, HUABIO is dedicated to developing curated, high-quality antibodies that advance innovation. We're passionate about the accuracy, efficiency, and consistency of our products. We devote our company mission to the disruption of an ...